Log in

NASDAQ:AXDXAccelerate Diagnostics Stock Price, Forecast & News

$15.05
+0.52 (+3.58 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$14.55
Now: $15.05
$15.30
50-Day Range
$9.36
MA: $14.83
$17.71
52-Week Range
$4.53
Now: $15.05
$22.13
Volume173,096 shs
Average Volume421,238 shs
Market Capitalization$831.83 million
P/E RatioN/A
Dividend YieldN/A
Beta2.84
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Read More
Accelerate Diagnostics logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.2Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.88 out of 5 stars


Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXDX
CUSIPN/A
Phone520-365-3100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.30 million
Book Value($0.14) per share

Profitability

Net Income$-84,310,000.00
Net Margins-845.43%

Miscellaneous

Employees287
Market Cap$831.83 million
Next Earnings Date8/6/2020 (Confirmed)
OptionableOptionable
$15.05
+0.52 (+3.58 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions

How has Accelerate Diagnostics' stock been impacted by COVID-19 (Coronavirus)?

Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AXDX stock has increased by 41.8% and is now trading at $15.05.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Accelerate Diagnostics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 sell rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Accelerate Diagnostics
.

When is Accelerate Diagnostics' next earnings date?

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for Accelerate Diagnostics
.

How can I listen to Accelerate Diagnostics' earnings call?

Accelerate Diagnostics will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics Inc (NASDAQ:AXDX) released its quarterly earnings results on Thursday, May, 7th. The medical research company reported ($0.39) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.39). The medical research company had revenue of $2.34 million for the quarter, compared to the consensus estimate of $2.40 million. Accelerate Diagnostics had a negative net margin of 845.43% and a negative return on equity of 5,681.44%.
View Accelerate Diagnostics' earnings history
.

What price target have analysts set for AXDX?

3 brokerages have issued twelve-month price objectives for Accelerate Diagnostics' stock. Their forecasts range from $14.00 to $19.00. On average, they anticipate Accelerate Diagnostics' stock price to reach $16.33 in the next twelve months. This suggests a possible upside of 8.5% from the stock's current price.
View analysts' price targets for Accelerate Diagnostics
.

Has Accelerate Diagnostics been receiving favorable news coverage?

News articles about AXDX stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Accelerate Diagnostics earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days.
View the latest news about Accelerate Diagnostics
.

Are investors shorting Accelerate Diagnostics?

Accelerate Diagnostics saw a decrease in short interest in the month of July. As of July 15th, there was short interest totaling 15,760,000 shares, a decrease of 8.9% from the June 30th total of 17,300,000 shares. Based on an average daily volume of 497,200 shares, the days-to-cover ratio is currently 31.7 days. Currently, 56.3% of the company's shares are sold short.
View Accelerate Diagnostics' Current Options Chain
.

Who are some of Accelerate Diagnostics' key competitors?

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AbbVie (ABBV), AT&T (T) and Exelixis (EXEL).

Who are Accelerate Diagnostics' key executives?

Accelerate Diagnostics' management team includes the following people:
  • Mr. Lawrence Mehren, Pres, CEO, Director and Interim Head of Europe, Middle East & Africa (Age 53)
  • Mr. Steve Reichling, Chief Financial Officer (Age 41)
  • Mr. Ron Price, Sr. VP & Head of Commercial Operations - Americas (Age 55)
  • Mr. Kurt Reinhardt, Head of Operations
  • Dr. Romney M. Humphries, Chief Scientific Officer (Age 38)

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Chicago Capital LLC (1.37%), UBS Group AG (0.15%) and SG Americas Securities LLC (0.03%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, John Patience, Romney Humphries, Steven Reichling and Thomas D Brown.
View institutional ownership trends for Accelerate Diagnostics
.

Which major investors are selling Accelerate Diagnostics stock?

AXDX stock was sold by a variety of institutional investors in the last quarter, including Chicago Capital LLC, and UBS Group AG.
View insider buying and selling activity for Accelerate Diagnostics
.

Which major investors are buying Accelerate Diagnostics stock?

AXDX stock was purchased by a variety of institutional investors in the last quarter, including SG Americas Securities LLC. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, John Patience, Steven Reichling, and Thomas D Brown.
View insider buying and selling activity for Accelerate Diagnostics
.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $15.05.

How big of a company is Accelerate Diagnostics?

Accelerate Diagnostics has a market capitalization of $831.83 million and generates $9.30 million in revenue each year. The medical research company earns $-84,310,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis. Accelerate Diagnostics employs 287 workers across the globe.

What is Accelerate Diagnostics' official website?

The official website for Accelerate Diagnostics is acceleratediagnostics.com.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.